Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;12(12):703-715.
doi: 10.1038/nrrheum.2016.147. Epub 2016 Sep 22.

Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles

Affiliations
Review

Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles

Frédéric Coutant et al. Nat Rev Rheumatol. 2016 Dec.

Abstract

Dendritic cells (DCs) are central regulators of the balance between immunity and tolerance, and alteration of the specialized DC system is a common feature of both systemic and tissue-specific autoimmune diseases. Increasing evidence indicates that the heterogeneity and the remarkable functional diversity of DC subsets might be differentially affected in autoimmune disorders, which accounts for different pathologies. This Review discusses recent findings that support this concept and provides a new conceptual overview of the altered function and distribution of DCs in autoimmune disorders. The discussion will focus on systemic lupus erythematosus - a prototype of a multi-organ disease - as well as rheumatoid arthritis and idiopathic inflammatory myopathies, pathologies characterized by tissue-specific lesions. Studies on these diseases have revealed common and disease-specific changes in DC distribution and in critical DC functions, such as phagocytosis, cytokine secretion and migration. An improved understanding of the roles of altered DC distribution and/or disturbed key functions in these autoimmune diseases will pave the way for the development of new therapies aiming at reducing immunogenicity and at enhancing the tolerogenic capacity of DCs. Although some tolerogenic DCs have already been introduced in the clinic, the successful translation of other DC-based therapies will require considerable research efforts.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arthritis Rheum. 2013 Apr;65(4):1011-21 - PubMed
    1. J Exp Med. 2002 Jul 1;196 (1):135-40 - PubMed
    1. Immunol Rev. 2010 Jan;233(1):267-85 - PubMed
    1. Arthritis Rheum. 2000 Aug;43(8):1831-5 - PubMed
    1. Lupus. 2009 Jul;18(8):676-81 - PubMed

MeSH terms